Logo

CombiMatrix Stock Loses Ground Gained on Yesterday s Novavax Agreement

Nov 10, 2005

NEW YORK, Nov. 9 (GenomeWeb News) - Shares in CombiMatrix were down 5.9 percent, or $.12, at $1.91 in mid-afternoon trading after gaining 5.1 percent yesterday on news that it was part of an alliance aimed at monitoring vaccine production.

 

As GenomeWeb News reported yesterday, CombiMatrix and Novavax plan to develop a technique monitoring vaccine production. Traditional flu-vaccine development and production is too slow to accommodate rapidly evolving flu strains, the company said. CombiMatrix's technique improves the process by tracking the genetic fidelity of the genes encoding the vaccine.

 

CombiMatrix and Novavax will test the method's efficacy on Novavax's VLP process for producing H5N1 bird flu vaccine.

 

Financial details were not disclosed.

Breaking News
The Scan

Shape of Them All

According to BBC News, researchers have developed a protein structure database that includes much of the human proteome.

For Flu and More

The Wall Street Journal reports that several vaccine developers are working on mRNA-based vaccines for influenza.

To Boost Women

China's Ministry of Science and Technology aims to boost the number of female researchers through a new policy, reports the South China Morning Post.

Science Papers Describe Approach to Predict Chemotherapeutic Response, Role of Transcriptional Noise

In Science this week: neural network to predict chemotherapeutic response in cancer patients, and more.